Brady Family Wealth LLC Sells 22,025 Shares of Medtronic PLC $MDT

Brady Family Wealth LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT) by 89.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,492 shares of the medical technology company’s stock after selling 22,025 shares during the quarter. Brady Family Wealth LLC’s holdings in Medtronic were worth $215,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDT. Kennebec Savings Bank raised its position in Medtronic by 1.2% in the third quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company’s stock valued at $794,000 after purchasing an additional 110 shares during the period. Petredis Investment Advisors LLC lifted its stake in shares of Medtronic by 0.4% in the 3rd quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock valued at $2,275,000 after purchasing an additional 114 shares during the last quarter. Aviance Capital Partners LLC grew its holdings in shares of Medtronic by 2.1% during the 3rd quarter. Aviance Capital Partners LLC now owns 5,469 shares of the medical technology company’s stock worth $472,000 after purchasing an additional 114 shares during the period. Arlington Trust Co LLC grew its holdings in shares of Medtronic by 11.6% during the 2nd quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after purchasing an additional 120 shares during the period. Finally, Bank & Trust Co grew its holdings in shares of Medtronic by 2.8% during the 2nd quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after purchasing an additional 121 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 0.0%

Shares of NYSE MDT opened at $104.92 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $92.47 and its two-hundred day moving average is $88.43. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The firm has a market cap of $134.21 billion, a price-to-earnings ratio of 25.84, a PEG ratio of 2.46 and a beta of 0.56.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts predict that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 2.7%. Medtronic’s dividend payout ratio is presently 70.94%.

Analyst Upgrades and Downgrades

MDT has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their price objective on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 2nd. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. BTIG Research lowered their target price on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Eighteen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic and Recor reported real-world evidence of gains from renal denervation, potentially strengthening evidence for the treatment and its commercial prospects. The article provides no specific results in the supplied summary. Medtronic, Recor deliver real-world evidence of renal denervation gains
• Positive Sentiment: Medtronic reached a fresh 52-week high, signaling strong recent share-price momentum, although the milestone itself does not establish a change in fundamentals. Medtronic Breaks to $105 for a New 52-Week High
• Positive Sentiment: A new educational initiative with the Michael J. Fox Foundation aims to help people with Parkinson’s and caregivers understand deep brain stimulation. Greater awareness could support consideration of Medtronic’s established treatment, though any sales impact is uncertain. Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson’s Understand Deep Brain Stimulation
• Neutral Sentiment: Medtronic will report fiscal second-quarter 2027 results on November 24. The announcement sets a date for a potential market catalyst but offers no new guidance or results. Medtronic to announce financial results for its second quarter of fiscal year 2027
• Negative Sentiment: A reported analyst consensus price target of $102.88 is below the roughly $105 level cited in recent coverage, which could suggest limited expected upside at that estimate. Medtronic PLC Stock Has Consensus Price Target of $102.88 According to Analysts

Insider Buying and Selling

In related news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Geoffrey Martha sold 50,000 shares of Medtronic stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 61,903 shares of company stock valued at $5,889,203. Corporate insiders own 0.27% of the company’s stock.

About Medtronic

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.